Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
618.12B
Market cap618.12B
Price-Earnings ratio
29.96
Price-Earnings ratio29.96
Dividend yield
2.04%
Dividend yield2.04%
Average volume
6.99M
Average volume6.99M
High today
$258.58
High today$258.58
Low today
$251.95
Low today$251.95
Open price
$256.22
Open price$256.22
Volume
6.05M
Volume6.05M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$184.66
52 Week low$184.66

Stock Snapshot

With a market cap of 618.12B, Johnson & Johnson(JNJ) trades at $256.30. The stock has a price-to-earnings ratio of 29.96 and currently yields dividends of 2.04%.

As of 2026-10-08, Johnson & Johnson(JNJ) stock has fluctuated between $251.95 and $258.58. The current price stands at $256.30, placing the stock +1.7% above today's low and -0.9% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 6.05M, compared to an average daily volume of 6.99M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

JNJ News

Reuters 3h
US House Speaker Johnson weighs 'next chapter' if Republicans lose majority-Fox News - Reuters

...

US House Speaker Johnson weighs 'next chapter' if Republicans lose majority-Fox News - Reuters
The Motley Fool 7h
Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect

Johnson & Johnson (JNJ -1.78%) has many qualities. It is one of the largest healthcare companies in the world and boasts an incredibly diversified business and...

Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect
Zacks 9h
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in t...

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

24/7 Wall St. 10h
Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not

Investing Pfizer’s Yield Is Three Times Bigger. Johnson & Johnson’s Dividend Has Something Pfizer Does Not Pfizer's yield towers over Johnson and Johnson's, but...

Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not
Simply Wall St 1d
Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock?

Johnson & Johnson reported new two-year Phase 3 ICONIC-TOTAL results showing ICOTYDE maintained skin clearance and a consistent safety profile through Week 112...

Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock?
24/7 Wall St. 1d
Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?

Investing Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy? Johnson & Johnson just logged its 64th straight year of dividend growth, but b...

Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
24/7 Wall St. 1d
The Crash-Proof Portfolio: 5 Elite Dividend Stocks Built to Survive a Market Meltdown

Investing The Crash-Proof Portfolio: 5 Elite Dividend Stocks Built to Survive a Market Meltdown Market indicators are flashing red heading into October, and inv...

The Crash-Proof Portfolio: 5 Elite Dividend Stocks Built to Survive a Market Meltdown
24/7 Wall St. 2d
Two of America's Biggest Money Voices Give Opposite Advice on Dividend Stocks

Personal Finance Two of America’s Biggest Money Voices Give Opposite Advice on Dividend Stocks Dave Ramsey and Suze Orman have built careers on helping people r...

Two of America's Biggest Money Voices Give Opposite Advice on Dividend Stocks
Zacks 2d
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?

Johnson & Johnson's (JNJ Quick QuoteJNJ - Free Report) medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascu...

Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
TipRanks 2d
Johnson & Johnson price target raised to $290 from $287 at RBC Capital

RBC Capital analyst Trung Huynh raised the firm’s price target on Johnson & Johnson to $290 from $287 and keeps an Outperform rating on the shares. The firm not...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.